Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  European Neuropsychopharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.euroneuro.2008.08.009PMID 18823760
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Relationship between depression severity entry criteria and antidepressant clinical trial outcomes.

  2007cited by this paper
• Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram.

  2006influential reference
• The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures.

  2006cited by this paper
• Does elimination of placebo responders in a placebo run‐in increase the treatment effect in randomized clinical trials? A meta‐analytic evaluation

  2004cited by this paper
• Relative sensitivity of the Montgomery–Åsberg depression rating scale, the Hamilton depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials: a replication analysis

  2004influential reference
• Research design features and patient characteristics associated with the outcome of antidepressant clinical trials.

  2004influential reference
• Frequency of Positive Studies Among Fixed and Flexible Dose Antidepressant Clinical Trials: An Analysis of the Food and Drug Administraton Summary Basis of Approval Reports

  2003influential reference
• The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach

  2003cited by this paper
• Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials

  2002influential reference
• Severity of Depression and Response to Antidepressants and Placebo: An Analysis of the Food and Drug Administration Database

  2002influential reference
• Placebo response in studies of major depression: variable, substantial, and growing.

  2002influential reference
• The Double-Blind Variable Placebo Lead-in Period: Results From Two Antidepressant Clinical Trials

  2001cited by this paper
• The responsiveness of the Hamilton Depression Rating Scale.

  2000cited by this paper
• Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: The absence of an effect related to agitation and suicidal behavior

  1997cited by this paper
• DSM-IV: Diagnostic and Statistical Manual of Mental Disorders

  1994cited by this paper
• Does a Placebo Run-In or a Placebo Treatment Cell Affect the Efficacy of Antidepressant Medications?

  1994cited by this paper
• Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program.

  1991cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• Research diagnostic criteria: rationale and reliability.

  1978cited by this paper
• Diagnostic criteria for use in psychiatric research.

  1972cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressants.

  2026cites this paper
• Expectancy Effects, Failure of Blinding Integrity, and Placebo Response in Trials of Treatments for Psychiatric Disorders: A Narrative Review.

  2025cites this paper
• A scoping review of placebo and nocebo responses and effects: insights for clinical trials and practice

  2025cites this paper
• Antidepressant medications: a comprehensive review of efficacy, safety, and future directions

  2025cites this paper
• Adjunctive brexpiprazole in patients with major depressive disorder who show minimal or partial response to antidepressant treatment: post hoc analysis of randomized controlled trials

  2025cites this paper
• Minimizing placebo responses in clinical trials.

  2025cites this paper
• Current Progress in Targeted Pharmacotherapy to Treat Symptoms of Major Depressive Disorder: Moving From Broad-Spectrum Treatments to Precision Psychiatry.

  2025cites this paper
• The loss of efficacy of fluoxetine in pediatric depression: explanations, lack of acknowledgment, and implications for other treatments.

  2025cites this paper
• Pulmonary Vein Isolation versus SHAM-pulmonary vein isolation for symptomatic relief in patients with Atrial Fibrillation - design and rationale of the PVI-SHAM-AF trial.

  2025cites this paper
• Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder

  2025cites this paper
• Patient-reported efficacy of adjunctive brexpiprazole in major depressive disorder in a phase 4, open-label, interventional study

  2025cites this paper
• Signal detection and placebo response in schizophrenia: parallels with depression.

  2025cites this paper
• Comparison of Different Machine Learning Methodologies for Predicting the Non‐Specific Treatment Response in Placebo Controlled Major Depressive Disorder Clinical Trials

  2025cites this paper
• Transforming the evidence landscape in mental health with platform trials

  2025cites this paper
• Chronobiologic treatments for mood disorders.

  2025cites this paper
• A novel artificial intelligence-based methodology to predict non-specific response to treatment.

  2025cites this paper
• Predicting Treatment Outcome Based on Resting-State Functional Connectivity in Internalizing Mental Disorders: A Systematic Review and Meta-Analysis.

  2024cites this paper
• Adjunctive cariprazine for major depressive disorder: a systematic review and meta-analysis

  2024influential citation
• Placebo effects of repetitive transcranial magnetic stimulation on negative symptoms and cognition in patients with schizophrenia spectrum disorders: a systematic review and meta-analysis

  2024cites this paper
• Exploring the Characteristics of Gut Microbiota Associated with Depression via the Depression Assessment Scales

  2024cites this paper
• The Impact of Development on Antidepressant and Placebo Response in Anxiety Disorders: A Bayesian Hierarchical Meta-Analytic Examination of Randomized Controlled Trials in Children, Adolescents, and Adults

  2024cites this paper
• Uncertainty of treatment efficacy moderates placebo effects on reinforcement learning

  2024cites this paper
• Novel multi-modal methodology to investigate placebo response in major depressive disorder.

  2024cites this paper
• Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD).

  2024cites this paper
• Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial

  2024cites this paper
• What should constitute a control condition in psychedelic drug trials?

  2024cites this paper
• Advancing the personalized advantage index (PAI): a systematic review and application in two large multi-site samples in anxiety disorders

  2024cites this paper
• Antidepressants in the acute treatment of post-traumatic stress disorder in adults: a systematic review and meta-analysis

  2024influential citation
• Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7–17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies

  2024cites this paper
• A Systematic Review of Antidepressants and Psychotherapy Commonly Used in the Treatment of Late Life Depression for Their Effects on Cognition.

  2024cites this paper
• Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting

  2023cites this paper
• Efficacy and safety of n-3 fatty acids supplementation on depression: a systematic review and dose–response meta-analysis of randomised controlled trials

  2023cites this paper
• Design Considerations for a Phase II Platform Trial in Major Depressive Disorder

  2023cites this paper
• A randomized, double-blind, placebo-controlled phase 2 study of intratympanic OTO-313 in patients with moderate to severe subjective tinnitus.

  2023cites this paper
• Efficacy of Intratympanic OTO-104 for the Treatment of Ménière's Disease: The Outcome of Three Randomized, Double-Blind, Placebo-Controlled Studies

  2023cites this paper
• Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.

  2023cites this paper
• Efficacy and acceptability of vitamin D supplements for depressed patients: A systematic review and meta-analysis of randomized controlled trials.

  2023cites this paper
• Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators

  2023cites this paper
• Novel ultrasound neuromodulation therapy with transcranial pulse stimulation (TPS) in Parkinson’s disease: a first retrospective analysis

  2023cites this paper
• Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review

  2023cites this paper
• A new method for analyzing clinical trials in depression based on individual propensity to respond to placebo estimated using artificial intelligence.

  2023cites this paper
• Imaginary pills and open-label placebos can reduce test anxiety by means of placebo mechanisms

  2023cites this paper
• Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: Post hoc analysis of Inventory of Depressive Symptomatology Self-Report data.

  2023cites this paper
• Life Engagement Improvement Following Initiation of Brexpiprazole Treatment in Patients with MDD: A Naturalistic, Retrospective Real-World Study

  2023cites this paper
• How should we design future mechanistic and/or efficacy clinical trials?

  2023cites this paper
• Recent Developments in Pharmacotherapy of Depression: Bench to Bedside

  2023cites this paper
• When does the placebo effect have an impact on network meta-analysis results?

  2023cites this paper
• The Nocebo Response in Pharmacologic Treatments of Primary Headache: A Systematic Review and Meta‐Analysis

  2022cites this paper
• The role of placebo response in the efficacy outcome assessment in viloxazine extended‐release pivotal trials in paediatric subjects with attention‐deficit/hyperactivity disorder

  2022cites this paper
• Efficacy and acceptability of next step treatment strategies in adults with treatment-resistant major depressive disorder: protocol for systematic review and network meta-analysis

  2022cites this paper
• Placebo Response in Trials of Negative Symptoms in Schizophrenia: A Critical Reassessment of the Evidence

  2022cites this paper
• Pharmacotherapy for late-life depression

  2022cites this paper
• Skin conductance while facing emotional pictures at day 7 helps predicting antidepressant response at three months in patients with a major depressive episode.

  2022cites this paper
• Antidepressants in children and adolescents with major depressive disorder and the influence of placebo response: A meta-analysis.

  2022cites this paper
• Using Artificial Intelligence-based Methods to Address the Placebo Response in Clinical Trials.

  2022cites this paper
• Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: A post hoc analysis of four clinical studies.

  2022cites this paper
• Gut microbiome-wide association study of depressive symptoms

  2022cites this paper
• Placebo administration for dry eye disease: a level I evidence based systematic review and meta-analysis

  2022cites this paper
• Evolutionary Aspects of Diverse Microbial Exposures and Mental Health: Focus on "Old Friends" and Stress Resilience.

  2022cites this paper
• Who benefits most from expectancy effects? A combined neuroimaging and antidepressant trial in depressed older adults

  2021cites this paper
• Gut microbiome-wide association study of depression

  2021cites this paper
• Placebo Response and Its Predictors in Attention Deficit Hyperactivity Disorder: A Meta-Analysis and Comparison of Meta-Regression and MetaForest

  2021cites this paper
• Antipsychotic Monotherapy for Major Depressive Disorder: A Systematic Review and Meta-Analysis

  2021cites this paper
• POLYHYMNIA Mood – Empowering people to cope with depression through music listening

  2021cites this paper
• Does the placebo effect on hot flashes depend on the placebo dose?

  2021cites this paper
• A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD.

  2021cites this paper
• Blinding and expectancy confounds in psychedelic randomized controlled trials

  2021cites this paper
• Transcriptional-regulatory convergence across functional MDD risk variants identified by massively parallel reporter assays

  2021cites this paper
• Serotonin Transporter Genetic Variation and Antidepressant Response and Tolerability: A Systematic Review and Meta-Analysis

  2021cites this paper
• Treatment of Symptomatic Convergence Insufficiency in Children Enrolled in the Convergence Insufficiency Treatment Trial–Attention & Reading Trial: A Randomized Clinical Trial

  2021cites this paper
• The Placebo and Nocebo Responses in Clinical Trials in Inflammatory Bowel Diseases

  2021cites this paper
• PreTA: A network meta-analysis ranking metric measuring the probability of being preferable than the average treatment

  2020cites this paper
• „Old Friends“, Immunregulation und Stressresilienz

  2020cites this paper
• Esketamine/ketamine for treatment-resistant depression

  2020cites this paper
• Placebo response in trials of drug treatments for cancer-related fatigue: a systematic review, meta-analysis and meta-regression

  2020cites this paper
• A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine

  2020cites this paper
• Success and efficiency of phase 2/3 adjunctive trials for MDD funded by industry: a systematic review

  2020cites this paper
• Moxibustion at ‘Danzhong’ (RN17) and ‘Guanyuan’ (RN4) for fatigue symptom in patients with depression

  2020cites this paper
• Nocebo and lessebo effects.

  2020cites this paper
• „Old Friends“, Immunregulation und Stressresilienz

  2020cites this paper
• Slowed Processing Speed Disrupts Patient Expectancy in Late Life Depression.

  2020cites this paper
• Nocebo Response in the Pharmacological Management of Overactive Bladder: A Systematic Review and Meta-analysis.

  2020cites this paper
• Dose‐response relationship of selective serotonin reuptake inhibitors

  2020cites this paper
• Network meta‐analysis results against a fictional treatment of average performance: Treatment effects and ranking metric

  2020cites this paper
• Nocebo and lessebo effects

  2020cites this paper
• Comments on Expectancy, Cognition, and Antidepressant Response in Late Life Depression.

  2020cites this paper
• John D. Loeser Award Lecture: Size does matter, but it isn't everything: the challenge of modest treatment effects in chronic pain clinical trials

  2020cites this paper
• Design and conduct of confirmatory chronic pain clinical trials

  2020cites this paper
• Why we need more research into the placebo response in psychiatry

  2020cites this paper
• A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression

  2020cites this paper
• Historical Controls in Randomized Clinical Trials: Opportunities and Challenges

  2020cites this paper
• Efficacy of Triple Chronotherapy in unipolar and bipolar depression: A systematic review of the available evidence.

  2020cites this paper
• Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment

  2020cites this paper
• Raising Placebo Efficacy in Antidepressant Trials Across Decades Explained by Small-Study Effects: A Meta-Reanalysis

  2020cites this paper
• Placebo Effect in the Treatment of Depression and Anxiety

  2019cites this paper
• Management of Late-Life Depression.

  2019cites this paper
• Comparative Efficacy and Acceptability of Pharmacological, Psychotherapeutic, and Combination Treatments in Adults With Posttraumatic Stress Disorder: A Network Meta-analysis.

  2019cites this paper
• Placebo Effects in Psychotherapy: A Framework

  2019influential citation
• Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis

  2019cites this paper
• No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: systematic review

  2019cites this paper